Hormonal treatment of prostate cancer (primary hormonal therapy)
DOI: https://doi.org/10.22591/magyurol.2023.2.horvatha.93
Authors:
Horváth András dr., Szalontai János dr., Riesz Péter dr., Szűcs Miklós dr., Nyirády Péter dr.
Semmelweis Egyetem, Urológiai Klinika és Andrológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
Summary
The basis of the treatment of advanced and metastatic prostate cancer is androgen deprivation therapy, where the androgen secretion of testis is suppressed in different ways. The most frequently used form is chemical castration with LHRH agonist/antagonist injections. For locally advanced prostate cancer a combination of hormone therapy (ADT) with local treatment (radiotherapy or radical prostatectomy) is recommended to improve survival. In case of confirmed lymph node positivity after radical surgery early adjuvant hormone therapy improves tumour-specific survival, which can be combined with irradiation of the prostate bed as an additional benefit. Even in metastatic prostate cancer combination treatments are the standard first-line therapies, primarily with the combined administration of ADT and ARPI (abiraterone, apalutamide, enzalutamide).